Literature DB >> 28804835

Chromogenic Factor VIII Assays for Improved Diagnosis of Hemophilia A.

Susan Rodgers1, Elizabeth Duncan2.   

Abstract

Hemophilia A is an inherited bleeding disorder caused by a reduced level of factor VIII coagulant activity (FVIII:C) in blood. Bleeding episodes may occur spontaneously in the severe form of hemophilia or after trauma in the milder forms. It is important that patients are diagnosed correctly, which includes placing them into the correct severity category of the disorder so that appropriate treatment can be given. Diagnosis is made by determination of the amount of FVIII:C in the blood, usually using a one-stage factor VIII:C assay. However, approximately one third of patients with mild or moderate hemophilia will have much lower results by the chromogenic assay, with some of them having normal results by the one-stage assay. The chromogenic factor VIII assay is used in some specialized hemophilia reference centers and is recommended for the diagnosis of mild hemophilia A, as this assay is considered to better reflect the severity status of hemophilia patients than the one-stage assay.

Entities:  

Keywords:  Chromogenic; Coagulation; Factor VIII; Hemophilia

Mesh:

Substances:

Year:  2017        PMID: 28804835     DOI: 10.1007/978-1-4939-7196-1_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

Review 1.  Consensus recommendations on appropriate coagulation tests during emicizumab administration in Saudi Arabia.

Authors:  Tarek Owaidah; Abdulakareem Almomen; Ahmed Tarawah; Ashraf Warsi; Fawaz Alkasim; Hazzaa Alzahrani; Mahassen Saleh; Ohoud Kashari; Wasil Jastaniah
Journal:  Am J Blood Res       Date:  2022-06-20

2.  Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!

Authors:  Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Res Pract Thromb Haemost       Date:  2022-03-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.